Xenetic Partner Gets Israeli Approval for Exploratory CAR T-Cell Lymphoma Study
XBIO sits 63% above its 52-week low of $1.9.
Summary
Xenetic Biosciences' collaboration partner, PeriNess Ltd., received approval from the Israeli Ministry of Health to initiate an exploratory clinical study. The study will evaluate DNase I in combination with anti-CD19 CAR T cells for large B-cell lymphoma patients. This follows the company's presentation of compelling preclinical data for its DNase I technology at ASCO 2026 on June 1st. For a micro-cap biotech, this approval marks a significant step, moving their technology from preclinical studies into human clinical trials and providing early clinical validation.
At the time of this announcement, XBIO was trading at $3.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.7M. The 52-week trading range was $1.90 to $13.93. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.